In addition, a novel inhibitor of ALKBH5, named TD19, has been identified to irreversibly modify residues C100 and C267, thus preventing ALKBH5 from binding to m6A-containing RNA and displays promising anti-cancer efficacy in AML and glioblastoma multiforme cell lines (142). This evidence concerns the gene ALKBH5 and acute myeloid leukemia.